By Colin Kellaher

 

AbbVie Inc. (ABBV) on Thursday said it is ending its research and development program for Rovalpituzumab Tesirine, or Rova-T, after the investigational antibody-drug conjugate showed no survival benefit in a phase 3 study in advanced small-cell lung cancer.

The North Chicago, Ill., biopharmaceutical company said it will prioritize other development programs within its oncology pipeline.

AbbVie said an independent data monitoring committee recommended terminating the study of Rova-T as a first-line maintenance therapy for advanced small-cell lung cancer due to lack of survival benefit for patients receiving Rova-T compared with placebo.

Small-cell lung cancer is difficult to treat and accounts for 10% to 15% of all lung cancers.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

August 29, 2019 09:19 ET (13:19 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more AbbVie Charts.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more AbbVie Charts.